FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) |
|---|
| Instruction 1(b). |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

| 1. Name and Address of Reporting Person* BOGER JOSHUA S | 2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | |
|--|---|--|--|--|--|--|--|
| (Last) (First) (Middle) | <u>MA</u> [VRTX] | X Officer (give title Other (specify below) below) | | | | | |
| C/O VERTEX PHARMACEUTICALS INCORPORATED | 3. Date of Earliest Transaction (Month/Day/Year) 08/20/2008 | President & CEO | | | | | |
| 130 WAVERLY STREET | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| (Street) | | X Form filed by One Reporting Person | | | | | |
| CAMBRIDGE MA 02139 | | Form filed by More than One Reporting Person | | | | | |
| (City) (State) (Zip) | | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | | | | 5. Amount of Securities Beneficially Owned Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership |
|---------------------------------|--|---|---|---|--------|---------------|-----------------------------------|---|---|---|
| | | | Code | v | Amount | (A) or (D) | Price | Reported Transaction(s) (Instr. 3 and 4) | | (Instr. 4) |
| Common Stock | 08/20/2008 | | М | | 12,400 | A | \$10.19 | 1,107,444 | D | |
| Common Stock | 08/20/2008 | | S ⁽¹⁾ | | 4,466 | D | \$26 .4 ⁽²⁾⁽⁵⁾ | 1,102,978 | D | |
| Common Stock | 08/20/2008 | | S ⁽¹⁾ | | 7,100 | D | \$27.61(3)(5) | 1,095,878 | D | |
| Common Stock | 08/20/2008 | | S ⁽¹⁾ | | 834 | D | \$28 .17 ⁽⁴⁾⁽⁵⁾ | 1,095,044 | D | |
| Common Stock | | | | | | | | 12,445 | Ι | 401(k) |
| Common Stock | | | | | | | | 207,500 | Ι | Shares in trust ⁽⁶⁾ |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| | (c.g., puis, cans, warrants, options, convertible securities) | | | | | | | | | | | | | | |
|---|---|--|---|------------------------------|---|-----|--------|--|--------------------|---|--|---|--|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Stock Options | \$10.19 | 08/20/2008 | | М | | | 12,400 | (7) | 09/16/2008 | Common Stock | 12,400 | \$ <mark>0</mark> | 37,578 | D | |

Explanation of Responses:

1. Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.

2. Open market sales reported on this line occurred at a weighted average price of \$26.40 (range \$26.05 to \$27.00).

3. Open market sales reported on this line occurred at a weighted average price of \$27.61 (range \$27.05 to \$28.00).

4. Open market sales reported on this line occurred at a weighted average price of \$28.17 (range \$28.06 to \$28.33).

5. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

6. Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.

7. Fully vested. Remarks:

Kenneth S. Boger, Attorney-In-Fact 08/21/2008

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.